cerebello-spinal direct current stimulation
DevicecsDCS influences both ascending and descending spinal pathways and reflex excitability, promoting prolonged functional neuroplastic changes.
Other names: csDCS
NCT Number: NCT07073287
The aim of this clinical trial is to determine if cerebello-spinal direct current stimulation (csDCS) is effective in treating gait disorders in individuals with chronic stroke. Additionally, the trial seeks to evaluate the safety of this technique.
The primary objectives include:
Investigating whether cerebello-spinal direct current stimulation improves gait and functional mobility in participants with chronic stroke.
Assessing any potential side effects associated with the method.
Researchers will conduct a comparative analysis between cerebello-spinal direct current stimulation and a sham procedure (which mimics the stimulation without any actual effect) to assess its effectiveness in addressing gait disorders and enhancing mobility.
Participants in the trial will:
Undergo cerebello-spinal direct current stimulation combined with treadmill training or a sham procedure with treadmill training daily over a two-week period.
Interested in participating?
Request Info18 year–75 year
All sexes
Interventional
Phase 2
Federal University of Paraiba, João Pessoa, Paraíba, Brazil
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
csDCS influences both ascending and descending spinal pathways and reflex excitability, promoting prolonged functional neuroplastic changes.
Other names: csDCS
Masking for cerebello-spinal direct current stimulation involves the electric current stopping after 30 seconds, providing a sensation without producing neuromodulation.
Time frame: Baseline, post-treatment (2 weeks) and follow up after 30 days
The Timed-Up and Go (TUG) test is used to evaluate an individual´s capacity to stand up, walk, and sit down. During the test, the participants are timed from the moment they begin to stand up until they are seated again.
Time frame: Baseline, post-treatment (2 weeks) and follow up after 30 days
Self-reported independence is assessed using the Functional Ambulation Categories (FAC). Scores range from 0 (inability to walk even with external help) to 5 (normal ambulation).
Time frame: Baseline, post-treatment (2 weeks) and follow up after 30 days
Motor function of the lower limbs is assessed using the Fugl-Meyer Assessment, where scores range from 0 (indicating the worst motor function) to 28 (indicating normal motor function).
Time frame: Baseline, post-treatment (2 weeks) and follow up after 30 days
Capacity to maintain balance during various tasks is assessed using the Mini Balance Evaluation System (MiniBEST-test). Its scores range from 0 to 28 points. Lower scores indicate poor balance, while higher scores reflect better balance.
Time frame: Upon completion of the two-week intervention
Evaluation of how the participant describe the perceived change in their condition since the treatment started, using the Patient Global Impression of Change (PGM). This scale assesses the change in activity limitations, symptoms, emotions, and overall quality of life since the beginning of treatment, ranging from no change or worsening to significant improvement that made a considerable difference. A score of one indicates no change, while a score of seven represents a substantial improvement.
Time frame: Baseline, post-treatment (2 weeks) and follow up after 30 days
Muscle tone disorders will be assessed using the Modified Ashworth Scale, which measures spasticity by grading muscle resistance during passive stretching. The scale ranges from 0 to 4, where 0 indicates no increase in muscle tone, and 4 represents a limb that is rigid in flexion or extension.
Contact information is provided by the study sponsor or research team.
Universidade Federal de Pernambuco
Other
Efficacy of Cerebello-spinal Direct Current Stimulation on Functional Mobility in Chronic Stroke Patients
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07661849
Brain Diseases, Cardiovascular Diseases
El Paso, Texas, United States
View Trial DetailsNCT07642154
Brain Diseases, Cardiovascular Diseases
Lahore, Punjab Province, Pakistan
View Trial DetailsNCT07565363
Brain Diseases, Cardiovascular Diseases
Istanbul, Turkey (Türkiye)
View Trial DetailsNCT04682223
Aphasia, Brain Diseases
Columbia, South Carolina, United States
View Trial Details